Our group has recently explored the basis for these distinctly adverse outcomes in TP53‐aberrant MDS and AML using clonal dynamic modeling, which suggested that TP53‐aberrant clones drive malignant hematopoiesis and constitute measurable residual disease (MRD) for most patients, which in turn contributes to relapse [3]. Here, TP53 is linked to acute myeloid leukemia.